...publicly traded biotechnology companies, including cancer companies Cytogen Corp. (acquired by EUSA Pharma Inc.) and VioQuest Pharmaceuticals Inc....

...publicly traded biotechnology companies, including cancer companies Cytogen Corp. (acquired by EUSA Pharma Inc.) and VioQuest Pharmaceuticals Inc....

...Infinity's first foray into biotech. Through an earlier fund it invested in two U.S. companies: Chiral Quest...

...of the Sutent plus Lenocta. Pfizer Inc. markets Sutent to treat renal and gastrointestinal cancers. VioQuest Pharmaceuticals Inc.'s...

...and is in Phase II testing to treat kidney, metastatic colon and several other cancers. VioQuest Pharmaceuticals Inc.'s...

...one of the diseases on the FDAAA list. In its 10-Q filing in August 2008, VioQuest Pharmaceuticals Inc....
...to partner or license the priority review voucher that VioQuest expects to receive." In October, VioQuest...
...Medical Service of Washington , Washington, D.C. U.S. Food and Drug Administration (FDA), Rockville, Md. VioQuest Pharmaceuticals Inc....

...NASDAQ:CRXL) Dukoral vaccine Prevent cholera Approved ex-U.S. Paladin Labs (TSX:PLB) Impavido miltefosine Leishmaniasis Approved ex-U.S. VioQuest...

...FDA notified VioQuest that its topical Xyfid 1% uracil to treat dermatoses would be regulated as...
...FDA alternative pathways for approval of Xyfid because an NDA submission would be "years away." VioQuest Pharmaceuticals Inc....

...OTCBB:ARNI), Fairfield, N.J. Business: Cancer Hired: Brian Lenz as CFO, formerly CFO and treasurer of VioQuest Pharmaceuticals Inc. WIR...